A unique influenza vaccine candidate that’s inhaled and based on technology developed by University of Wisconsin-Madison researchers is safe and could bolster protection against seasonal and pandemic influenza for people vulnerable to severe disease when they receive it in addition to the annual flu shot.Those are the results of a randomized, controlled trial of the vaccine candidate, administered in nasal spray form in conjunction with the annual shot to a group of 65- to 85-year-olds in 2022.
Your privacy is our priority
- Hosted on Secure cloud-based hosting
- SOC II Type 1
- HIPAA compliant
- 2FA authentication
- End-to-end data encryption
- Your health data will not be sold or used without your consent. Ever.
